The 10% left behind

Based on the untapped potential of bio-medical prevention, UNAIDS has recently devised a strategy known as 90-90-90: 90% of all infected people tested, 90% of diagnosed people undergoing treatment, and 90% of people treated reaching an undetectable viral load. Now echoed by many involved in the fight against HIV/AIDS, UNAIDS is loudly contending that this is how we […]

Lire la suite

Pill-identified bodies

In November 2004, Warning conducted an interview with American activist Eric Rofes. For a small splinter-group spun off from Act Up-Paris, it would become a major turning-point for us. Act Up’s pessimistic culture had instilled in us a moralizing attitude towards sexuality founded on a fundamental wariness of male homosexual behaviour. Added to this was […]

Lire la suite

The demonization of people using Truvada for prevention has backfired

A gay man living with HIV since 1995, Jim Pickett is Director of Prevention Advocacy and Gay Men’s Health at AIDS Foundation of Chicago (AFC). His new prevention technology portfolio consists of projects addressing ARV-based prevention, including PrEP and microbicides, and he leads the global advocacy efforts of IRMA – International Rectal Microbicide Advocates. He […]

Lire la suite

CATIE and Canada : still and always late !

Canada — On March 20th, James Wilton, the Biomedical Science of HIV Prevention Project Coordinator, of Canada’s gateway to information about HIV/AIDS (CATIE), gave an extremely problematic interview for the online journal Positive Lite (http://positivelite.com/content/new…). There is indeed a result of inaccuracies and outdated arguments. Thus, Mr. Wilton explains, as one might read and hear the following statements […]

Lire la suite

(PrEP) The ANRS-IPERGAY study should be discontinued : prevention research in France is in disarray

Warning considers that, given the current international scientific consensus, the placebo arm of the IPERGAY study does not meet ethical standards and must be immediately interrupted in the interest of protecting the health of gay men participating in study. Warning also requests that a temporary authorization for the use of oral PrEP be granted in France by the […]

Lire la suite

PrEP = 1$

Indeed, following the encouraging results of iPrEx [1], an expert committee of the U.S. Food and Drug Administration (FDA) recently recommended the marketing of Truvada for prophylaxis [2], whereas the French ANRS has launched IPERGAY [3] for several months. But this new stage in the medicalization of sexuality dear to Michel Foucault remains controversial. However, the pharmaco-sexuality does not […]

Lire la suite

Struggle against HIV or domination of the community ?

Michael Scarce is someone that makes you reflect a lot. He is renown in publishing one of the first analyses about barebacking phenomenon [1] and by drawing up the first sexual harm risk reduction rules [2]. Writer, researcher and also activist, Michael has recently published an article which caught up our attention and encourage us to ask him an interview. […]

Lire la suite

Seroadaptation instead of serosorting : a broader concept and a more precise process model

HIV transmission risk reduction strategies depend on the serostatus of each partner engaged in a sexual exchange. Serosorting is one of these strategies and consists in selecting sexual partners according to their HIV serostatus. Besides, other strategies exist and may be included with serosorting in the broader concept of seroadaptation. DESCRIPTIONIn 2004, the serosorting concept […]

Lire la suite